Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.

Yochum ZA, Cades J, Wang H, Chatterjee S, Simons BW, O'Brien JP, Khetarpal SK, Lemtiri-Chlieh G, Myers KV, Huang EH, Rudin CM, Tran PT, Burns TF.

Oncogene. 2019 Jan;38(5):656-670. doi: 10.1038/s41388-018-0482-y. Epub 2018 Aug 31.

2.

A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer.

Yochum ZA, Cades J, Mazzacurati L, Neumann NM, Khetarpal SK, Chatterjee S, Wang H, Attar MA, Huang EH, Chatley SN, Nugent K, Somasundaram A, Engh JA, Ewald AJ, Cho YJ, Rudin CM, Tran PT, Burns TF.

Mol Cancer Res. 2017 Dec;15(12):1764-1776. doi: 10.1158/1541-7786.MCR-17-0298. Epub 2017 Aug 29.

3.

Ganetespib radiosensitization for liver cancer therapy.

Chettiar ST, Malek R, Annadanam A, Nugent KM, Kato Y, Wang H, Cades JA, Taparra K, Belcaid Z, Ballew M, Manmiller S, Proia D, Lim M, Anders RA, Herman JM, Tran PT.

Cancer Biol Ther. 2016 Apr 2;17(4):457-66. doi: 10.1080/15384047.2016.1156258.

4.

Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cells.

Gajula RP, Chettiar ST, Williams RD, Nugent K, Kato Y, Wang H, Malek R, Taparra K, Cades J, Annadanam A, Yoon AR, Fertig E, Firulli BA, Mazzacurati L, Burns TF, Firulli AB, An SS, Tran PT.

Neoplasia. 2015 Jan;17(1):16-31. doi: 10.1016/j.neo.2014.10.009.

5.

A PWWP domain-containing protein targets the NuA3 acetyltransferase complex via histone H3 lysine 36 trimethylation to coordinate transcriptional elongation at coding regions.

Gilbert TM, McDaniel SL, Byrum SD, Cades JA, Dancy BC, Wade H, Tackett AJ, Strahl BD, Taverna SD.

Mol Cell Proteomics. 2014 Nov;13(11):2883-95. doi: 10.1074/mcp.M114.038224. Epub 2014 Aug 6.

6.

The twist box domain is required for Twist1-induced prostate cancer metastasis.

Gajula RP, Chettiar ST, Williams RD, Thiyagarajan S, Kato Y, Aziz K, Wang R, Gandhi N, Wild AT, Vesuna F, Ma J, Salih T, Cades J, Fertig E, Biswal S, Burns TF, Chung CH, Rudin CM, Herman JM, Hales RK, Raman V, An SS, Tran PT.

Mol Cancer Res. 2013 Nov;11(11):1387-400. doi: 10.1158/1541-7786.MCR-13-0218-T. Epub 2013 Aug 27.

7.

Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.

Wild AT, Gandhi N, Chettiar ST, Aziz K, Gajula RP, Williams RD, Kumar R, Taparra K, Zeng J, Cades JA, Velarde E, Menon S, Geschwind JF, Cosgrove D, Pawlik TM, Maitra A, Wong J, Hales RK, Torbenson MS, Herman JM, Tran PT.

PLoS One. 2013 Jun 6;8(6):e65726. doi: 10.1371/journal.pone.0065726. Print 2013.

8.

Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.

Gandhi N, Wild AT, Chettiar ST, Aziz K, Kato Y, Gajula RP, Williams RD, Cades JA, Annadanam A, Song D, Zhang Y, Hales RK, Herman JM, Armour E, DeWeese TL, Schaeffer EM, Tran PT.

Cancer Biol Ther. 2013 Apr;14(4):347-56. doi: 10.4161/cbt.23626. Epub 2013 Jan 28.

9.

Evaluation of glucuronide metabolite stability in dried blood spots.

Bowen CL, Volpatti J, Cades J, Licea-Perez H, Evans CA.

Bioanalysis. 2012 Dec;4(23):2823-32. doi: 10.4155/bio.12.269.

PMID:
23216122
10.

Antibiotic prescribing in response to bacterial isolates in the intensive care unit.

Buising KL, Thursky KA, Bak N, Skull S, Street A, Presneill JJ, Cades JF, Brown GV.

Anaesth Intensive Care. 2005 Oct;33(5):571-7.

11.

Purification and characterization of different types of exfoliative toxin from Staphylococcus aureus.

Johnson AD, Spero L, Cades JS, de Cicco BT.

Infect Immun. 1979 Jun;24(3):679-84.

Supplemental Content

Support Center